Real-World Evidence Backs Venetoclax-Based Treatment in Chronic Lymphocytic Lymphoma

May 11, 2023

A real-world evidence (RWE) study presented at this year’s ISPOR meeting shows that venetoclax-based treatment regimens improve patient outcomes in chronic lymphocytic lymphoma (CLL). Patients on venetoclax (Venclexta) had reduced rates of treatment initiation and had a longer time before new treatments or death. The study was based off electronic health records (EHR) from CLL patients across the US.

According to Nichole Tucker, “According to the study results from those treated in the first-line setting, 73.4% of patients did not have subsequent therapy, and notably 93.0% of patients who received VenO did not require subsequent therapy. The mDOT [median duration of treatment) was 12.7 months among the VenO-treated population, 19 months among those treated with VenR, and 3.3 months with monotherapy. At a median follow-up of 23.1 months, TTNT-D was not reached among patients treated with either VenO or VenR. For patients treated with venetoclax monotherapy, the median TTNT-D [time to new treatment or death] was 13.5 months.”

To read more, click here.